Physician profile
Vincent Falanga
NPI 1376501825
$1,076.33
in general payments reported to CMS, 2019-2025
12 companies · $881 in 2025
The $881 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.34 · 2024: $173 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $216.27 | 2024-2025 | Tremfya |
| Abbvie INC. | $195.76 | 2024-2025 | |
| Amgen INC. | $141.39 | 2025 | Otezla |
| Galderma Laboratories, L.P. | $122.70 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $105.17 | 2025 | Taltz, Ebglyss |
| Ucb, INC. | $97.92 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $43.76 | 2025 | |
| Arcutis Biotherapeutics, INC. | $42.70 | 2025 | Zoryve |
| Incyte Corporation | $40.78 | 2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $23.97 | 2024 | Sotyktu |
| Strata Skin Sciences, INC. | $23.57 | 2025 | Xtrac |
| Polarityte, INC. | $22.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Falanga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.